Persecutory ideation and a history of cannabis use

Schizophrenia Research

Volumn 148, Issue 1-3, 2013, Pages 122-125

  Freeman, Daniel ^a   Morrison, Paul D ^b   Murray, Robin M ^b   Evans, Nicole ^a   Lister, Rachel ^a   Dunn, Graham ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cannabis; Delusions; Paranoia; Persecutory ideation

Indexed keywords

CANNABIS;

ADOLESCENT; ADULT; AGED; ARTICLE; CANNABIS ADDICTION; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PARANOIA; PERSECUTORY DELUSION; PRIORITY JOURNAL; SCORING SYSTEM;

CANNABIS; DELUSIONS; PARANOIA; PERSECUTORY IDEATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMMUNITY HEALTH PLANNING; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PARANOID DISORDERS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; YOUNG ADULT;

EID: 84881029286     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.06.008     Document Type: Article

References (33)

1. Andréasson S., Engström A., Allebeck P., Rydberg U. Cannabis and schizophrenia. Lancet 1987, 330:1483-1486.
2. Arendt M., Mortensen P., Rosenberg R., Pedersen C., Waltoft B. Familial predisposition for psychiatric disorder. Arch. Gen. Psychiatry 2008, 65:1269-1274.
3. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T. Cannabis use in adolescence and risk for adult psychosis. BMJ 2002, 325:1212-1213.
4. Bak M., Drukker M., van Os J., Delespaul P. Hospital comorbidity bias and the concept of schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 2005, 40:817-821.
5. Casadio P., Fernandes C., Murray R., Di Forti M. Cannabis use in young people. Neurosci. Biobehav. Rev. 2011, 35:1779-1787.
6. D'Souza D., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.-T., Braley G., Gueorguieva R., Krystal J. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals. Neuropsychopharmacology 2004, 29:1558-1572.
7. D'Souza D., Sewell R., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:413-431.
8. Di Forti M., Lyegbem C., Sallis H., Kolliakou A., Falcone A., Paparelli A., et al. Confirmation that the AKT1 (rs2494732) genortype influences the risk of psychosis in cannabis users. Biol. Psychiatry 2012, (http://dx.doi.org/10.1016/j.biopsych.2012.06.020).
9. Fenigstein A., Vanable P.A. Paranoia and self-consciousness. J. Personal. Soc. Psychol. 1992, 62:129-138.
10. Fergusson D., Horwood L., Ridder E. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005, 100:354-366.
11. Freeman D., Garety P.A. Comments on the content of persecutory delusions: does the definition need clarification?. Br. J. Clin. Psychol. 2000, 39:407-414.
12. Freeman D., Gittins M., Pugh K., Antley A., Slater M., Dunn G. What makes one person paranoid and another person anxious? The differential prediction of social anxiety and persecutory ideation in an experimental situation. Psychol. Med. 2008, 38:1121-1132.
13. Freeman D., Pugh K., Antley A., Slater M., Bebbington P., Gittins M., Dunn G., Kuipers E., Fowler D., Garety P.A. A virtual reality study of paranoid thinking in the general population. Br. J. Psychiatry 2008, 192:258-263.
14. Freeman D., Pugh K., Vorontsova N., Antley A., Slater M. Testing the continuum of delusional beliefs: an experimental study using virtual reality. J. Abnorm. Psychol. 2010, 119:83-92.
15. Freeman D., McManus S., Brugha T., Meltzer H., Jenkins R., Bebbington P. Concomitants of paranoia in the general population. Psychol. Med. 2011, 41:923-936.
16. Garety P., Gittins M., Jolley S., Bebbington P., Dunn G., Kuipers E., Fowler D., Freeman D. Differences in cognitive and emotional processes between persecutory and grandiose delusions. Schizophr. Bull. 2013, 39:629-639.
17. Green C., Freeman D., Kuipers E., Bebbington P., Fowler D., Dunn G., Garety P.A. Measuring ideas of persecution and reference: the Green et al. Paranoid Thought Scales (G-PTS). Psychol. Med. 2008, 38:101-111.
18. Hall W., Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry 2007, 20:393-397.
19. IBM SPSS Statistics Version 20. Release 20.0.0 2011, IBM Corporation.
20. Johns L., Cannon M., Singleton N., Murray R., Farrell M., Brugha T., Bebbington P., Jenkins R., Meltzer H. Prevalence and correlates of self-reported psychotic symptoms in the British population. Br. J. Psychiatry 2004, 185:298-305.
21. Kaymaz N., Drukker M., Lieb R., Wittchen H.-U., werbeloff N., Weiser M., Lataster T., van Os J. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help -seeking population-based samples? A systematic review and meta-analysis, enriched with new results. Psychol. Med. 2012, 42:2239-2253.
22. Kuepper R., Morrison P., van Os J., Murray R., Kenis G., Henquet C. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr. Res. 2010, 121:107-117.
23. Kuepper R., van Os J., Lien R., Wittchen H.-U., Höffler M., Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms. Br. Med. J. 2011, 342. 10.1136/bmj.d738 DOI:10.1136%2Fbmj.d738.
24. Linscott R., van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults. Psychol. Med. 2012, 10.1017/S0033291712001626.
25. Maric N., Myin-Germeys I., Delespaul P., de Graaf R., Vollebergh W., van Os J. Is our concept of schizophrenia influenced by Berkson's bias?. Soc. Psychiatry Psychiatr. Epidemiol. 2004, 39:600-605.
26. McGuire P., Jones P., Harvey I., Williams M., McGuffin P., Murray R. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr. Res. 1995, 15:277-281.
27. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T., Jones P., Burke M. Systematic review of cannabis use and risk of developing psychotic or affective mental health outcomes. Lancet 2007, 370:319-328.
28. 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol. Med. 2009, 39:1607-1616.
29. Murray R., Morrison P., Henquet C., Di Forti M. Cannabis, the mind and society. Nat. Rev. Neurosci. 2007, 8:885-895.
30. Office Home Drug Misuse Declared: Findings from the 2011/12 Crime Survey for England and Wales 2012, Home Office, London. Second edition.
31. Peralta V., Cuesta M.J. Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders. Schizophr. Res. 1999, 38:13-26.
32. Plomin R., Haworth C.M.A., Davis O.S.P. Common disorders are quantitative traits. Nat. Rev. Genet. 2009, 10:872-878.
33. Vázquez-Barquero J.L., Lastra I., Nuñez M.J.C., Castanedo S.H., Dunn G. Patterns of positive and negative symptoms in first episode schizophrenia. Br. J. Psychiatry 1996, 168:693-701.